Genomic Health (GHDX) Prelim. Q4, FY15 Revenues Miss Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
Genomic Health (GHDX) Plans Oncotype SEQ Launch for mid-2016
January 11, 2016 8:17 AM ESTGenomic Health, Inc. (Nasdaq: GHDX) announced plans to launch its first liquid biopsy test, Oncotype SEQ, in mid-2016. The test is a blood-based mutation panel that uses next-generation sequencing to identify select actionable genomic alterations for the treatment of patients with late-stage lung, breast, colon, melanoma, ovarian or gastrointestinal cancer. As a fit-for-purpose panel, Oncotype SEQ is designed... More
Piper Jaffray Downgrades Genomic Health Inc. (GHDX) to Neutral
January 11, 2016 6:48 AM ESTPiper Jaffray downgraded Genomic Health Inc. (NASDAQ: GHDX) from Overweight to Neutral with a price target of $32.00 (from $36.00) as they shift their focus to 2017.
Analyst William Quirk commented: "We are downgrading Genomic Health on a contrarian call as we look beyond the 2016 reacceleration to 2017 expectations. We... More
